{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:37:53Z","timestamp":1759797473429,"version":"build-2065373602"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,6]]},"DOI":"10.7759\/cureus.93926","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:01:44Z","timestamp":1759752104000},"source":"Crossref","is-referenced-by-count":0,"title":["Delayed-Onset Immune-Mediated Hepatitis Following Pembrolizumab Discontinuation: A Case Report"],"prefix":"10.7759","author":[{"given":"Connor","family":"Barry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwunonso B","family":"Ubanatu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Bozym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang PF","year":"2017","unstructured":"Wang PF, Chen Y, Song SY, et al.. Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017, 8:730. 10.3389\/fphar.2017.00730","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen Y","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018, 31:965-73. 10.1038\/s41379-018-0013-y","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin E","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, et al.. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018, 68:1181-90. 10.1016\/j.jhep.2018.01.033","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14078","article-title":"Diagnostic guide for immune checkpoint inhibitor-induced liver injury","volume":"54","author":"Ito T","year":"2024","unstructured":"Ito T, Takeuchi Y, Mizuno K, et al.. Diagnostic guide for immune checkpoint inhibitor-induced liver injury. Hepatol Res. 2024, 54:719-26. 10.1111\/hepr.14078","journal-title":"Hepatol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.907591","article-title":"Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology","volume":"13","author":"Hercun J","year":"2022","unstructured":"Hercun J, Vincent C, Bilodeau M, Lapierre P. Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology. Front Immunol. 2022, 13:907591. 10.3389\/fimmu.2022.907591","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.719236","article-title":"Case report: Severe immune-related cholestatic hepatitis and subsequent pneumonia after pembrolizumab therapy in a geriatic patient with metastic gastric cancer","volume":"8","author":"Yang H","year":"2021","unstructured":"Yang H, Zhou C, Yuan F, Guo L, Yang L, Shi Y, Zhang J. Case report: Severe immune-related cholestatic hepatitis and subsequent pneumonia after pembrolizumab therapy in a geriatic patient with metastic gastric cancer. Front Med (Lausanne). 2021, 8:719236. 10.3389\/fmed.2021.719236","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650292","article-title":"Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis","volume":"11","author":"Fu J","year":"2021","unstructured":"Fu J, Li WZ, McGrath NA, Lai CW, Brar G, Xiang YQ, Xie C. Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis. Front Oncol. 2021, 11:650292. 10.3389\/fonc.2021.650292","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu Z","year":"2022","unstructured":"Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives. Front Pharmacol. 2022, 13:1077468. 10.3389\/fphar.2022.1077468","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2015.06.06","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid J","year":"2015","unstructured":"Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015, 4:560-75. 10.3978\/j.issn.2218-6751.2015.06.06","journal-title":"Transl Lung Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goz044","article-title":"Histologic patterns of liver injury induced by anti-PD-1 therapy","volume":"8","author":"Zhang D","year":"2020","unstructured":"Zhang D, Hart J, Ding X, et al.. Histologic patterns of liver injury induced by anti-PD-1 therapy. Gastroenterol Rep (Oxf). 2020, 8:50-5. 10.1093\/gastro\/goz044","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31089","article-title":"Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma","volume":"71","author":"Stuart L","year":"2020","unstructured":"Stuart L, Lambourne B, Turner P, Jones DE, Plummer R, Cresti N, Dyson JK. Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma. Hepatology. 2020, 71:2164-6. 10.1002\/hep.31089","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000096","article-title":"Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity","volume":"23","author":"Karim G","year":"2024","unstructured":"Karim G, Reddy M, Mobin N, Weisberg I, Dinani A. Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity. Clin Liver Dis (Hoboken). 2024, 23:e0096. 10.1097\/CLD.0000000000000096","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000525","article-title":"Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: a systematic review and meta-analysis","volume":"8","author":"Hwang SY","year":"2024","unstructured":"Hwang SY, Hsieh P, Zhang W. Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: a systematic review and meta-analysis. Hepatol Commun. 2024, 8:10.1097\/HC9.0000000000000525","journal-title":"Hepatol Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/386983-delayed-onset-immune-mediated-hepatitis-following-pembrolizumab-discontinuation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:01:46Z","timestamp":1759752106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/386983-delayed-onset-immune-mediated-hepatitis-following-pembrolizumab-discontinuation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.93926","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}